Pengaruh Pemberian Ekstrak Etil Asetat Ulva fasciatadelile dan Turbinaria decurrensbory terhadap Laju Pertumbuhan Tumor Kelenjar Susu Padamencit C3h

Thamrin Wikanta, Vita Fitria Handayani, Lestari Rahayu, Asri Pratitis, Puspita Eka Wuyung

Abstract


ABSTRACT

Breast cancer is the second mostly found disease after cervix cancer to Indonesian woman. Research on the effect of Ulva fasciata Delile and Turbinaria decurrensBory ethyl acetate extract feeding on the Adenocarcinoma mammaecell proliferation on C3H mice has been
conducted. Thirty experimental mice were devided into 6 treatment groups, i.e.: K-I, negative control; K-II, solvent control; K-III, given U. fasciata ethyl acetate extract dose of 41.32 mg/20 g BW (body weight); K-IV, given U. fasciataethyl acetate extract dose of 82.64 mg/20 g BW; K-V, given T. decurrensethyl acetate extract dose of 24.29 mg/20 g BW; and K-VI, given T. decurrens ethyl acetate extract dose of 48.59 mg/20 g BW. All treatments were given during 21 days. The mice body weight and tumor volume were measured and collected subsequently at every two days. Tumor doubling time was calculated at the end of research. Results showed that there was
a highly tumor growth inhibition on the K-IV shown by the high doubling time value. Tumor growth inhibition decreased according to the sequence as follows: K-IV (U. fasciata dose of 82.64 mg/20
g BW), K-V (T. decurrensdose of 24.29 mg/20 g BW), K-VI (T. decurrensdose of 48.59 mg/20 g BW) which equal to K-II (solvent control), K-III (U. fasciatadose of 41.32 mg/20 g BW), K-I
(negative control).


Keywords


ethyl acetate extract, Ulva fasciata, Turbinaria decurrens, breast tumor

Full Text:

PDF


DOI: http://dx.doi.org/10.15578/jpbkp.v6i1.92

Article Metrics

Abstract view : 357 times
PDF - 242 times

Refbacks

  • There are currently no refbacks.


JPBKP adalah Jurnal Ilmiah yang terindeks :


Creative Commons License

ISSN : 1907-9133(print), ISSN : 2406-9264(online)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.